Lumosa Therapeutics Co. Ltd.

Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company based in Taipei, Taiwan, that develops drugs for neurological and oncological diseases in Taiwan and elsewhere in Asia. Its products include Naldebain (LT-1001), an analgesic injection for postoperative pain. The company is also developing LT3001, which has completed Phase 2b clinical trials for acute ischemic stroke; LT6001, in pre-clinical trials for neurological disorders; and CS028, in the pre-clinical stage for solid tumors. It also engages in investment, new drug development consulting, and service and transfer of techniques. Formerly known as SunTen Phytotech Co., Ltd., it changed its name to Lumosa Therapeutics Co., Ltd. in June 2014 and was incorporated in 2000.